Facebook
Twitter
LinkedIn
Forward
Gamechangers in Alopecia Areata: Targeted Therapies for Patient-Centered Care
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development and FDA-approval of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Moreover, these vital healthcare providers need education on disease pathophysiology, burden, and the impact this illness imparts on the whole patient. This 1-hour educational activity, originally presented live at the 21st Annual South Beach Symposium, addresses these gaps through clinical evidence-based discussion and case-based learning led by the foremost experts in treating AA.
This activity references foundational knowledge previously addressed in an educational primer activity. If you have not yet viewed this educational content, it can be accessed for additional CE credit here.
Target Audience
These activities are designed for an audience of U.S. based dermatologists, pediatric dermatologists, nurses, nurse practitioners, and/or physician assistants who treat alopecia areata and other medical dermatology conditions.
Learning Objectives
- Summarize the burden of disease for AA patients including psychosocial and medical comorbidities
- Review signaling pathways involved in the pathogenesis of alopecia areata
- Interpret clinical safety and efficacy data, as well as mechanisms of action, for emerging treatments of alopecia areata
- Apply knowledge of new and emerging therapies for optimal patient selection and treatment plan design
- Introductory Remarks (5 mins)
- Review of Educational Primer (15 mins)
- Didn't get a chance to view the educational primer? Click here to view now and receive additional CE credits!
- Patient Case Simulations (20 mins)
- Expert Roundtable Discussion: Key Pearls and Takeaways for Improved Patient Outcomes (20 mins)
Brittany G. Craiglow, MD
Adjunct Assistant Professor
Department of Dermatology
Yale University School of Medicine
New Haven, CT
Brett A. King, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, CT
Natasha A. Mesinkovska, MD, PhD
Associate Professor, Dermatology
UC Irvine School of Medicine
Irvine, CA
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse
1.0 ANCC contact hour
Commercial Support
This activity is supported by an educational grant from Pfizer.
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose
Disclosures | ||
Name | Relationship | Company |
Brittany Craiglow, MD | Consultant | Pfizer, Eli Lilly, Concert Pharmaceuticals - alopecia areata , Regeneron, Sanofi Genzyme - atopic dermatitis |
Speaker | Incyte - vitiligo | |
Brett King, MD, PhD | Advisor | Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio |
Consultant | Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio | |
Individual Stocks and stock options | BiologicsMD | |
Natasha Mesinkovska, MD, PhD | Advisor | Lilly |
Consultant | University of Southern California Irvine- Abbvie, Arcutis, Arena, BMS, Concert, Galderma, Merz, Lilly, Kadmon, Novartis, Pfizer | |
Researcher | Abbvie, BMS, Concert, Lilly, Pfizer | |
Speaker | Lilly | |
Speaker | Regeneron, Sanofi Genzyme, Verrica | |
Dorothy Caputo, MA, BSN, RN, Senior Director of Continuing Education & Compliance | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.